PSA
VELOCITY AND DOUBLING TIME
|
|
.
|
Orsted
DD, Bojesen SE, Kamstrup PR, Nordestgaard BG.
Long-term
Prostate-specific Antigen Velocity in Improved Classification of
Prostate Cancer Risk and Mortality.
Eur
Urol. 2013 Feb 4. doi:pii: S0302-2838(13)00097-3.
10.1016/j.eururo.2013.01.028. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
PREOPERATIVE
BIOMARKERS
|
|
.
|
D'Amico
AV, Chen MH.
Pretreatment
prostate-specific antigen velocity and the risk of death from
prostate cancer in the individual with low-risk prostate cancer.
J
Clin Oncol. 2009 Aug 1;27(22):3575-6. doi:
10.1200/JCO.2009.22.6068. Epub 2009 Jun 8.
Editorial
relating to:
O'Brien
MF et
al, Pretreatment
prostate-specific antigen (PSA) velocity and doubling time are
associated with outcome but neither improves prediction of outcome
beyond pretreatment PSA alone in patients treated with radical
prostatectomy. J
Clin Oncol. 2009 Aug 1;27(22):3591-7. doi:
10.1200/JCO.2008.19.9794. Epub 2009 Jun 8.
Source
| Full
text |
Similar
articles
|
|
|
.
|
O'Brien
MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino
PT, Eastham JA, Vickers AJ, Lilja H.
Pretreatment
prostate-specific antigen (PSA) velocity and doubling time are
associated with outcome but neither improves prediction of outcome
beyond pretreatment PSA alone in patients treated with radical
prostatectomy.
J
Clin Oncol. 2009 Aug 1;27(22):3591-7. doi:
10.1200/JCO.2008.19.9794. Epub 2009 Jun 8.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Patel
DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR.
Preoperative
PSA velocity is an independent prognostic factor for relapse after
radical prostatectomy.
J
Clin Oncol. 2005 Sep 1;23(25):6157-62. DOI:
10.1200/JCO.2005.01.2336
Source
| Full
text |
Similar
articles
|
|
|
.
|
Vickers
AJ, Savage C, O'Brien MF, Lilja H.
Systematic
review of pretreatment prostate-specific antigen velocity and
doubling time as predictors for prostate cancer.
J
Clin Oncol. 2009 Jan 20;27(3):398-403. doi:
10.1200/JCO.2008.18.1685. Epub 2008 Dec 8.
Source
| Full
text |
Similar
articles
|
|
|
POSTOPERATIVE
BIOMARKERS
|
|
|
|
Biochemical
recurrence
|
|
.
|
Freedland
SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC,
Partin AW.
Death
in patients with recurrent prostate cancer after radical
prostatectomy: prostate-specific antigen doubling time subgroups
and their associated contributions to all-cause mortality.
J
Clin Oncol. 2007 May 1;25(13):1765-71. DOI:
10.1200/JCO.2006.08.0572
Source
| Full
text |
Similar
articles
|
|
|
Clinical
progression
|
|
.
|
Roberts
SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
PSA
doubling time as a predictor of clinical progression after
biochemical failure following radical prostatectomy for prostate
cancer.
Mayo
Clin Proc. 2001 Jun;76(6):576-81. DOI:
https://doi.org/10.4065/76.6.576
Source
| Full
text |
Similar
articles
|
|
|
ACTIVE
SURVEILLANCE
|
|
.
|
Ross AE,
Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z,
Carter HB, Walsh PC.
Prostate-specific
antigen kinetics during follow-up are an unreliable trigger for
intervention in a prostate cancer surveillance program.
J
Clin Oncol. 2010 Jun 10;28(17):2810-6. doi:
10.1200/JCO.2009.25.7311. Epub 2010 May 3.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Whitson
JM, Carroll PR.
Active
surveillance for early-stage prostate cancer: defining the
triggers for intervention.
J
Clin Oncol. 2010 Jun 10;28(17):2807-9. doi:
10.1200/JCO.2010.28.5817. Epub 2010 May 3
Editorial
relating to:
Ross
AE et
al, Prostate-specific
antigen kinetics during follow-up are an unreliable trigger for
intervention in a prostate cancer surveillance program. J
Clin Oncol. 2010 Jun 10;28(17):2810-6. doi:
10.1200/JCO.2009.25.7311. Epub 2010 May 3
Source
| Full
text |
Similar
articles
|
|
|
UNTREATED
PATIENTS
|
|
.
|
Thomsen
FB, Brasso K, Berg KD, Gerds TA, Johansson JE, Angelsen A, Tammela
TL, Iversen P; Scandinavian Prostate Cancer Group.
Association
between PSA kinetics and cancer-specific mortality in patients
with localised prostate cancer: analysis of the placebo arm of the
SPCG-6 study.
Ann
Oncol. 2015 Dec 17. pii: mdv607. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
PREDICTION
OF FAILURE OF SALVAGE RT
|
|
.
|
King
CR, Presti JC, Brooks JD, Gill H, Spiotto MT.
Postoperative
prostate-specific antigen velocity independently predicts for
failure of salvage radiotherapy after prostatectomy.
Int
J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1472-7. DOI:
http://dx.doi.org/10.1016/j.ijrobp.2007.08.014 Epub 2007 Oct
11.
Source
|
Full
text |
Similar
articles
|
|
|
PREDICTION
OF CLINICAL OUTCOME AFTER RP
|
|
.
|
Roberts
SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
PSA
doubling time as a predictor of clinical progression after
biochemical failure following radical prostatectomy for prostate
cancer.
Mayo
Clin Proc. 2001 Jun;76(6):576-81.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Takeuchi
H, Ohori M, Tachibana M.
Clinical
significance of the prostate-specific antigen doubling time prior
to and following radical prostatectomy to predict the outcome of
prostate cancer.
Mol
Clin Oncol. 2017 Feb;6(2):249-254. doi: 10.3892/mco.2016.1116.
Epub 2016 Dec 22.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ,
Amling CL, Cooperberg MR, Freedland SJ.
Does early PSADT
(ePSADT) after Radical Prostatectomy, Calculated prior to PSA
Recurrence, Correlate with Prostate Cancer Outcomes? -A Report
from the SEARCH Database Group.
J Urol. 2017 Sep 1. pii:
S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.08.107. [Epub
ahead of print]
Source
| Full
text | Similar
articles
|
|
|
PSA
DOUBLING TIME WITH NON-METASTATIC CRPC
|
|
.
|
Howard
LE, Moreira D, De Hoedt A, Aronson WJ, Kane CJ, Amling CL,
Cooperberg MR, Terris MK, Freedland SJ.
Thresholds
for PSA doubling time in men with non-metastatic
castration-resistant prostate cancer.
BJU
Int. 2017 Mar 28. doi: 10.1111/bju.13856. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
PSA
NADIR AND MORTALITY FOLLOWING HT
|
|
.
|
Stewart
AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV.
Prostate-specific
antigen nadir and cancer-specific mortality following hormonal
therapy for prostate-specific antigen failure.
J
Clin Oncol. 2005 Sep 20;23(27):6556-60.
Source
| Full
text |
Similar
articles
|
|
|
TIME
TO PSA NADIR (TTN) AFTER PRIMARY ADT
|
|
.
|
Sasaki T, Sugimura Y.
The Importance of Time to
Prostate-Specific Antigen (PSA) Nadir after Primary Androgen
Deprivation Therapy in Hormone-Naïve Prostate Cancer
Patients.
J Clin Med. 2018 Dec 18;7(12). pii: E565. doi:
10.3390/jcm7120565.
Source
| Full
text |
Similar
articles
|
|
|
|
|
|
|
|
|
